BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, November 9, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Gilead details discovery of GS-4224, a potent PD-L1 inhibitor for cancer
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ACS Fall 2022
Gilead details discovery of GS-4224, a potent PD-L1 inhibitor for cancer
Aug. 31, 2022
No Comments
Gilead Sciences Inc. has disclosed the discovery and structure of the potent, oral small molecule programmed cell death 1 ligand 1 (PD-L1) inhibitor GS-4224 (evixapodlin).
BioWorld Science
Conferences
Cancer
Immuno-oncology